Sana Biotechnology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SANA Nasdaq 2834 www.sana.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sana Biotechnology, Inc.

Sana Biotechnology to Present at September 2026 Investor Conferences - Sep 1st, 2026 2:05 pm
Paratus Sciences Announces Updates to its Board of Directors - Aug 26th, 2026 6:00 am
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Aug 10th, 2026 2:05 pm
3 Promising Genomics Stocks to Add to Your Portfolio in 2026 - Jul 20th, 2026 8:49 am
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM - Jul 16th, 2026 3:11 pm
Sana (SANA) Upgraded to Buy: Here's What You Should Know - Jul 15th, 2026 10:00 am
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes - Jul 13th, 2026 6:00 am
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 - Jul 1st, 2026 7:00 am
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Jun 14th, 2026 10:48 pm
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor - Jun 11th, 2026 7:19 pm
Sana Biotechnology to Present at June 2026 Investor Conferences - May 27th, 2026 2:05 pm
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility - May 15th, 2026 7:00 am
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - May 12th, 2026 2:05 pm
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - May 11th, 2026 2:05 pm
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference - May 5th, 2026 2:05 pm
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting - Apr 27th, 2026 2:30 pm
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes - Apr 27th, 2026 12:22 am
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment - Apr 23rd, 2026 8:07 am
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6 - Apr 20th, 2026 3:30 pm
Kailera nets $625M in one of biotech’s biggest-ever IPOs - Apr 16th, 2026 2:38 pm